In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
- Even when HIV prevention drug is covered, other costs block treatmenton July 21, 2019 at 9:34 am
Three years ago, Corey Walsh, who was in a relationship with a man who was HIV-positive, got a prescription for Truvada, a drug approved by the Food and Drug Administration to prevent infection with ... […]
- Phase I Study of Pembrolizumab in People With HIV and Canceron July 21, 2019 at 8:45 am
People with HIV have been excluded from immuno-oncology (IO) studies. Anti-PD-1/PD-L1 therapies are approved for a growing number of cancers. We evaluated pembrolizumab (pembro) in people with HIV and ... […]
- With federal help, Alameda County and SF hope to cut rate of HIV infectionson July 20, 2019 at 4:15 am
Alameda County is one of 48 counties handpicked by federal public health officials to receive extra resources to end the spread of HIV over the next decade — and getting that done will take creative, ... […]
- East Bay commits to ending HIV/AIDS epidemic in the Bay Area, especially among the homeless communityon July 19, 2019 at 7:16 pm
OAKLAND, Calif. (KGO) -- The head of the Centers for Disease Control was on the ground in Oakland on Friday to assess the HIV/AIDS epidemic in Alameda County. AIDS is still very much a threat in ... […]
- Should HIV-positive workers be allowed in the sex industry? Some advocates say yeson July 19, 2019 at 5:14 pm
This article originally appeared in In These Times. Individuals who are HIV-positive are not permitted to participate in the adult entertainment industry. That standard is enforced through the ... […]
- Exploiting the CCR5 Receptor: Potential Avenue for HIV Cure?on July 19, 2019 at 6:30 am
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel ... […]
- Distinct epigenetic profiles in children with perinatally-acquired HIV on antiretroviral therapyon July 19, 2019 at 2:23 am
Perinatally-acquired HIV has persistent effects on long-term health outcomes, even after early treatment. We hypothesize that epigenetic indicators, such as DNA methylation, may elucidate cellular ... […]
- Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ARTon July 19, 2019 at 2:22 am
The HIV-1 reservoir is the major hurdle to a cure. We here evaluate viral and host characteristics associated with reservoir size and long-term dynamics in 1,057 individuals on suppressive ... […]
- Nigeria: HIV Rate Among Nigeria Prisoners Double That of General Population - UN Studyon July 18, 2019 at 10:18 pm
People in Nigerian prisons are two times more likely to be living with HIV than people in the general community, a new study has revealed. According to a National HIV Assessment Study, HIV among ... […]
- Tooth Wear in Patients Treated With HIV Anti-retroviral Therapyon July 18, 2019 at 9:24 pm
Background: The objective of this study was to elucidate the relationship between HIV anti-retroviral therapy and tooth wear. Methods: Assessment of tooth wear was conducted both with a survey ... […]
via Google News and Bing News